(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
India’s delayed climate plan sets modest emission target- Factbox-China's crewed lunar programme eyes astronaut landing by 2030
- NASA funds new tech for upcoming 'Super Hubble' to search for alien life: 'We intend to move with urgency'
- Instructions to Shield Your Gold Speculation from Possible Dangers: Fundamental Protections
- True to life Authenticity d: A Survey of \Certifiable Stories\ Narrative
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- Red Crescent: More than 100,000 civilian structures damaged in Iran
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- This Week In Space podcast: Episode 188 — A New NASA Leader Rises?
